ArticleAllergy, asthma & immunology research2026
Efficacy and Adherence of Combined Fluticasone Propionate and Azelastine Nasal Spray Versus Fluticasone Propionate Alone in Pediatric Allergic Rhinitis.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntranasal corticosteroids (INCS) and their combination with intranasal antihistamines (INCS/INAH) are treatment options for patients with allergic rhinitis (AR). Therefore, we aimed to prospectively compare these two different intranasal therapies regarding symptom scores, quality of life (QoL), and treatment adherence in adolescents.
methodsThe study included pediatric patients aged 12-18 years, diagnosed with moderate-to-severe AR. Patients' symptom severity at baseline and at the one- and two-month follow-ups was assessed using the Total Nasal Symptoms Score (TNSS); additionally, QoL and treatment adherence were measured via the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) and Medication Adherence Reporting Scale (MARS), respectively. These scores were compared between treatment groups.
resultsThe study included 79 patients with moderate-to-severe AR. Thirty-five patients (44.3%) had concomitant allergic diseases, and 28 (35.4%) had asthma. INCS (fluticasone propionate) therapy was started in 41 patients (51.9%), and combination therapy (azelastine hydrochloride + fluticasone propionate [AzeFlu]) was started in 38 patients (48.1%). Treatment adherence (MARS) was higher in the AzeFlu group (
conclusionsAzeFlu therapy may be preferred in patients with persistent symptoms and unresponsive to other treatments. Especially in adolescent children with persistent AR, AzeFlu should be considered as first-line treatment to increase treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.